Hepion pharmaceuticals expands sab with appointments of four liver disease kols

Edison, n.j., march 30, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, announces the addition of four new internationally recognized thought leaders to its scientific advisory board (“sab”), effective immediately.
HEPA Ratings Summary
HEPA Quant Ranking